Comera Life Sciences (CMRA) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends CMRA vs. ARDS, EVLO, GNCA, AMPE, EFTR, ONCSQ, ATNFW, LBPSW, AEHAW, and AIMDWShould you be buying Comera Life Sciences stock or one of its competitors? The main competitors of Comera Life Sciences include Aridis Pharmaceuticals (ARDS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCA), Ampio Pharmaceuticals (AMPE), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), and Ainos (AIMDW). These companies are all part of the "pharmaceutical products" industry. Comera Life Sciences vs. Aridis Pharmaceuticals Evelo Biosciences Genocea Biosciences Ampio Pharmaceuticals eFFECTOR Therapeutics OncoSec Medical 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Comera Life Sciences (NASDAQ:CMRA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability. Do institutionals and insiders hold more shares of CMRA or ARDS? 9.7% of Aridis Pharmaceuticals shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend CMRA or ARDS? Aridis Pharmaceuticals has a consensus price target of $2.00, suggesting a potential upside of 999,900.00%. Given Aridis Pharmaceuticals' higher possible upside, analysts clearly believe Aridis Pharmaceuticals is more favorable than Comera Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Comera Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAridis Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CMRA or ARDS more profitable? Company Net Margins Return on Equity Return on Assets Comera Life SciencesN/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A Which has more volatility & risk, CMRA or ARDS? Comera Life Sciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Does the media prefer CMRA or ARDS? In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score. Company Overall Sentiment Comera Life Sciences Neutral Aridis Pharmaceuticals Neutral Which has better earnings and valuation, CMRA or ARDS? Comera Life Sciences has higher earnings, but lower revenue than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioComera Life Sciences$630K0.00-$18M-$0.49N/AAridis Pharmaceuticals$3.09M0.00-$30.37M-$0.160.00 Does the MarketBeat Community favor CMRA or ARDS? Aridis Pharmaceuticals received 122 more outperform votes than Comera Life Sciences when rated by MarketBeat users. CompanyUnderperformOutperformComera Life SciencesN/AN/AAridis PharmaceuticalsOutperform Votes12261.00% Underperform Votes7839.00% SummaryAridis Pharmaceuticals beats Comera Life Sciences on 7 of the 10 factors compared between the two stocks. Ad Investing Daily2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.Click here. Get Comera Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRA vs. The Competition Export to ExcelMetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3,000.00$6.73B$5.02B$8.40BDividend YieldN/A7.94%7.52%4.16%P/E Ratio0.0012.04129.2216.66Price / SalesN/A269.201,719.4176.49Price / CashN/A46.0936.9133.53Price / BookN/A5.284.605.02Net Income-$18M$150.82M$114.45M$223.81M Comera Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRAComera Life SciencesN/AN/AN/AN/A$3,000.00$630,000.000.002ARDSAridis Pharmaceuticals0.8992 of 5 stars$0.00flat$2.00+999,900.0%-99.8%$11,000.00$3.09M0.0030Gap UpEVLOEvelo BiosciencesN/A$0.00flatN/A-99.9%$6,000.00N/A0.00120GNCAGenocea BiosciencesN/A$0.00flatN/AN/A$6,000.00$1.91M0.0070Analyst ForecastAMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.9%$3,000.00N/A0.0020EFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+5,999,900.0%-100.0%$2,000.00$3.55M0.0010ONCSQOncoSec MedicalN/A$0.00+∞N/AN/A$1,000.00N/A0.0040Gap UpATNFW180 Life SciencesN/A$0.01flatN/A+0.0%$0.00N/A0.007LBPSW4D pharmaN/A$0.04-25.7%N/AN/A$0.00$522,000.000.00N/AGap DownAEHAWAesther Healthcare AcquisitionN/A$0.16+6.2%N/A-40.6%$0.00N/A0.002Gap UpAIMDWAinosN/A$0.03-47.5%N/AN/A$0.00$65,122.000.0040Positive News Related Companies and Tools Related Companies ARDS Competitors EVLO Competitors GNCA Competitors AMPE Competitors EFTR Competitors ONCSQ Competitors ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMRA) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Comera Life Sciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Comera Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMRA Stock Alerts